PrisMax System
An advanced CRRT therapy system co-created with 650+ HCPs
We asked more than 650 ICU healthcare practitioners, from over 50 ICUs worldwide, what it would take to solve their greatest challenges in treating critically ill patients. The PrisMax System was designed to help meet these needs, building upon Vantive’s Prismaflex technology and more than 20 years of experience in advancing critical care delivery.
Compatible Products
Filter Sets & Catheters
Easily switch between therapies3
The PrisMax System delivers multiple modes of continuous renal replacement therapy (CRRT) without the need for additional equipment:
- CVVHDF: continuous veno-venous hemodiafiltration
- CVVHD: continuous veno-venous hemodialysis
- CVVH: continuous veno-venous hemofiltration
- SCUF: slow continuous ultrafiltration
Unlock the possibilities of the PrisMax System in the ICU
The PrisMax System can help improve treatment accuracy, increase workflow efficiency, and simplify therapy setup and delivery.
- Uses intelligent pump adjustments to help meet prescribed fluid removal targets and deliver accurate treatments.
- Allows treatment interruptions for up to 10 minutes per instance without impacting prescribed patient fluid removal.
- Reduce device interactions and treatment interruptions.
- Scale stability software helps prevent false alarms caused by bags moving.
- Advanced pressure management minimizes sudden pressure spikes caused by moving the patient.
- Rotates and tilts for multidirectional viewing.
- Large 15" display helps make checking therapy easier.
Our assessment of the PrisMax System across seven ICUs in six countries concluded that the device features several important enhancements that contribute to safety, efficiency and user friendliness. The launch of PrisMax is a big step forward for clinicians’ abilities to treat patients in the ICU more effectively.1
Marcus Broman, MD, Department of Perioperative and Intensive Care of Skåne University Hospital in Lund, Sweden, and lead author of a publication about these results.
Introducing the next-generation PrisMax 2 System,
co-created with clinicians to maximize confidence
To meet the ever-changing challenges in the ICU, clinicians need a system that is developed with their needs in mind. We took what we learned from PrisMax to evolve the PrisMax 2 System to advance the delivery of CRRT and multi-organ support therapies. We listened to healthcare professionals from across the world to identify core challenges in the ICU. The PrisMax 2 System is designed to address some of those challenges so providers can maximize their confidence in therapy delivery.
Enhanced interface
Designed for efficient and informed treatment decision-making
Wireless EMR connectivity
Save time and effort with auto-documentation for Electronic Medical Record (EMR) enabling data-driven decisions.
Important Safety Information
TherMax Blood Warmer Unit
Intended use
The TherMax Blood Warmer Accessory includes the Blood Warmer Unit and Blood Warmer Disposable. It is intended for use in combination with the PrisMax control unit using Prismaflex blood tubing sets for the warming of blood during extracorporeal blood circulation
Indications for use
The TherMax Blood Warmer Accessory is indicated for warming returning blood flow.
Contraindications
There are no known contraindications when used as intended, and within the specified operating conditions.
PrisMax
- The PrisMax control unit is intended for:
Continuous Renal Replacement Therapy (CRRT) for patients with acute renal failure and/or fluid overload.
- Therapeutic Plasma Exchange (TPE) therapy for patients with diseases where removal of plasma components is indicated.
- Hemoperfusion(HP) for patients with conditions where immediate removal of substances by adsorption is indicated.
All treatments administered via the PrisMax control unit must be prescribed by a physician.
WARNING!
Use only fluids designed for intravenous operations and are approved for CRRT/TPE/HP usage. Do not use fluids intended for any other usage like enteral feedings/lipids or cytotoxic drugs.
CONTRAINDICATIONS
There are no known absolute contraindications to Continuous Renal Replacement Therapies.
There are no known contraindications to Therapeutic Plasma Exchange.
There are no known contraindications to Hemoperfusion.
Regional Citrate Anticoagulation is contraindicated in patients with severe liver failure and shock with muscle hypoperfusion.
For the following conditions a careful assessment of the individual risk/benefit ratio has to be made by the treating physician (relative contraindications).
- Inability to establish vascular access.
- Severe hemodynamic instability.
- Known hypersensitivity to any component of the Prismaflex disposable set.
PRISMAFLEX
Intended use
The PRISMAFLEX control unit is intended for:
- Continuous Renal Replacement Therapy for patients with acute renal failure and/or fluid overload.
- Therapeutic Plasma Exchange Therapy for patients with diseases where removal of plasma components is indicated.
- Hemoperfusion for patients with conditions where immediate removal of substances by adsorption is indicated.
All treatments administered via the PRISMAFLEX control unit must be prescribed by a physician.
Contraindications
There are no known contraindications to Continuous Renal Replacement Therapies.
There are no known contraindications to Therapeutic Plasma Exchange.
There are no known contraindications to Hemoperfusion.
For contraindications that may apply to the disposable set selected for the therapy, refer to the Instructions For Use of the disposable set.
CE 0123
CE 2797
Vantive, Prismaflex, PrisMax and TherMax are trademarks of Vantive Health LLC or its affiliates.
References
-
Broman M, Bell M, Joannes-Boyau O, Ronco C. The novel PrisMax continuous renal replacement therapy system in a multinational, multicentre pilot setting. Blood Purif. 2018;46(3):220-227.
-
Vantive. TherMax Blood Warmer: Maximise Your Treatment Accuracy and System Performance. Vantive Health LLC; 2025.
-
Baxter Healthcare SA. TherMax Operator’s Manual. AW7006 Rev D. Baxter Healthcare SA; March 2025.